Ignite Creation Date:
2024-05-06 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 1:52 PM
Study NCT ID:
NCT04681768
Status:
RECRUITING
Last Update Posted:
2023-11-29
First Post:
2020-12-18
Brief Title:
Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients
Sponsor:
Organization:
Technical University of Munich
Study Design
Study Type:
OBSERVATIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
False
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
SAMPLES_WITH_DNA
Bio Spec Description:
Correlation analyses between circulating tumor DNA ctDNA protein tumormarkers and ORRCRR
Enrollment Count:
120
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
Observational Models:
| Name |
|---|
| Case-Only |
Time Perspective List:
Clinical Trial Statuses
| Name |
|---|
| 71231 |
Who Masked List: